Back to Search Results

Post-COVID syndrome, inflammation, and diabetes.

Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA. Electronic address: Ali.Rizvi@ucf.edu. Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA. Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates. Medical Research Center, Sultan Qaboos University, Muscat, Oman. Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman. Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates. IRCCS MultiMedica, Milan, Italy. Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey. Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Sweden. Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Italy. Department of Endocrinology, Singapore General Hospital, Singapore. Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia. Department of Endocrinology, Bharti Hospital & BRIDE, Karnal, India. Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary. The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates. Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Brazil. Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece. Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Diabetes Research Centre, Chennai, India. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy.

Journal of diabetes and its complications. 2022;(11):108336
Full text from:

Other resources

Abstract

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new-onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.

Methodological quality

Publication Type : Review

Metadata